Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU712908B2 - Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials - Google Patents
[go: Go Back, main page]

AU712908B2 - Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials - Google Patents

Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials Download PDF

Info

Publication number
AU712908B2
AU712908B2 AU49808/96A AU4980896A AU712908B2 AU 712908 B2 AU712908 B2 AU 712908B2 AU 49808/96 A AU49808/96 A AU 49808/96A AU 4980896 A AU4980896 A AU 4980896A AU 712908 B2 AU712908 B2 AU 712908B2
Authority
AU
Australia
Prior art keywords
quaternary ammonium
polymeric quaternary
chch
present
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU49808/96A
Other versions
AU4980896A (en
Inventor
Evan P. Kyba
Joonsup Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of AU4980896A publication Critical patent/AU4980896A/en
Application granted granted Critical
Publication of AU712908B2 publication Critical patent/AU712908B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/90Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62Quaternary ammonium compounds
    • C07C211/63Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Description

Polymeric Quaternary Ammonium Compounds and Their Use as Ophthalmic Antimicrobials Background of the Invention The present invention relates generally to a class of antimicrobials useful in pharmaceutical and cosmetic products. In particular, the present invention relates to polymeric quaternary ammonium compounds which are useful as disinfectants and preservatives for ophthalmic, pharmaceutical and contact lens care products.
Polymeric quaternary ammonium compounds as a class have been known for many years. British Patent No. 536,017 (August 30, 1941), assigned to E. I. DuPont de Nemours (the "DuPont Patent"), discloses linear polymeric quaternary ammonium compounds and methods for their preparation. The method of the DuPont Patent may be generically described as a condensation reaction between a lower alkyl dihalide and a difunctional ditertiary amine. Contemplated uses for the compounds of the DuPont Patent include their use in photographic processing, to treat leather, as mold inhibitors and pesticides, and as 15 modifying agents. There is no mention of use of these compounds as disinfectants or preservatives in pharmaceutical products.
U.S. Patents Nos. 3,931,319 (January 6, 1976), 4,001,432 (January 4, 1977) and 4,012,446 (March 15, 1977), all issued to Green, et al., disclose a group of high molecular weight "capped" linear polymeric quaternary ammonium compounds found to be effective microbiocides (antimicrobials). The Green, et al. compounds are "capped" in the sense that both ends of the chains terminate in quaternary ammonium moieties. In a continuation-inpart application, now U.S. Patent No. 4,027,020 (May 31, 1977), Green, et al. disclose a 0 process for making randomly capped linear polymeric quaternary ammonium compounds; that is, the polymers produced by the improved process include those with very short chain lengths as well as those having relatively long chain lengths. These compounds were also found to have antimicrobial activity.
a [N:\LIBC]04082:MEF U.S. Patents Nos. 4,407,791 (October 4, 1983) and 4,525,346 (June 25, 1985), both issued to Stark, disclose improved disinfecting solutions for contact lenses, wherein the aqueous solutions contain the Green, et al. polymers including the commercially known Onamer In addition, U.S.
Patent No. 5,037,647 (August 6, 1991), issued to Chowhan et al., discloses aqueous antimicrobial ophthalmic solutions containing Onamer M® in combination with an anionic complexing agent to prevent or to reduce binding of the polymer to contact lenses.
Summary of the Invention For purposes of this specification, disinfectants and/or preservatives shall be collectively referred to as "antimicrobials" and compounds having disinfecting and/or preserving efficacy shall be o referred to as compounds having "antimicrobial activity." In addition, the terms "polymeric quaternary ammonium compounds" or "polymers" shall hereinafter refer to polymeric quaternary ammonium compounds and their pharmaceutically acceptable salts, and the terms shall be used interchangeably :060: throughout this specification.
ooo It has now been found that certain polymeric quaternary ammonium compounds, of generic Z relationship to those disclosed in the DuPont Patent and the Green, et al. patents, are particularly suitable for use in ophthalmic compositions as antimicrobials. However, the polymers of the present 0 invention are unique in at least two respects: 1) it has been discovered that optimum performance for 900 .0 the indicated utility is achieved only for a narrow range of molecular size, length of the polymer; and 2) the polymers of the present invention are characterized by a terminal end group R, which is
N(CH
3 2 While applicants are bound by no theory, it appears that the polymer length and end capping function of the polymers of the present invention limit corneal toxicity, absorption and 00°0 o adsorption to contact lenses and maximise biocidal activity under the product designs and uses S disclosed herein.
0 0a Thus, in one embodiment of the invention, there is provided an ophthalmic composition comprising a polymeric quaternary ammonium compound of the structure:
WCH
2
CH-CHCH
2
-[N(CH
3 2
CH
2 CH CHCH2]n-W o 0nX wherein: W N(CH3)2; X is a pharmaceutically acceptable anion; and n is an integer from 16 to 32 and wherein the compound is present at a concentration between about 0.00001 and about percent by weight.
The ophthalmic compositions of the present invention comprise the polymers of the present invention. These compositions include: contact lens care products, such as chemical disinfecting and [R\LIBZZ]06203.doc NJC
I~
I 0
C.
C
0I
-C
C
0R*s3 00 S S1
C
CS
0 3 storage solutions and preserved saline solutions; and other types of ophthalmic compositions, such as artificial tears and topical pharmaceutical preparations.
Thus, in another embodiment of the invention, there is provided a method of disinfecting a contact lens, comprising contacting a contact lens with a composition comprising an ophthalmically acceptable vehicle and a disinfecting amount of a substantially pure form of a polymeric quaternary ammonium compound of the structure:
W-CH
2
CH=CHCH
2
-[N(CH
3 2
CH
2 CH CHCH 2
-W
nXwherein: W N(CH 3 2 X is a pharmaceutically acceptable anion; and n is an integer from 16 to 32.
Detailed Description of the invention Preferred polymers of the present invention are those of Structure below:
W-CH
2
CH=CHCH
2 [N+(H)CH3 2 CH2CHCHCH 2
W
nXwherein: W N(CH 3 2 X is a pharmaceutically acceptable anion, preferably a halide, particularly chloride; and n is an integer from 16 to 32, preferably from 20 to 24.
The polymers of the present invention can be made and purified by utilising the methods of the DuPont Patent or the Green, et al. patents to synthesise a polymeric mixture, then to separate the desired molecular weight fraction by chromatographic methods, by using dialysis membranes, by trituration, by a combination of these methods or by some other means.
The polymers of the present invention may be used as antimicrobials in ophthalmic compositions, particularly as disinfectants in contact lens care products and as preservatives in other types of ophthalmic compositions, such as artificial tears of topical pharmaceutical preparations. In general, the polymers of the present invention will be present in the compositions at a concentration between about 0.00001 and 1.0 percent by weight If used as a disinfectant, the polymers are preferably present at a concentration of between about 0.0005 and 0.5 wt%; if used as a preservative, the polymers [R \LIBZZ]06203.docNJC WO 97/29741 PCT/US96/01975 are present at a concentration between about 0.00005 and 0.05 wt%. It is preferred that the polymers are present at a concentration of between 0.001 and 0.05 wt% if used as a disinfectant and between 0.0001 and 0.01 wt% if used as a preservative.
The ophthalmic compositions of the present invention may additionally contain s other components, for example, ophthalmically acceptable buffers, tonicity agents, surfactants and therapeutic agents.
EXAMPLE
1,4-Dichloro-2-butene (1.88 grams 0.015 moles (mol)) was added dropwise to 2.13 g (0.015 mol) of N,N,NN-tetramethyl-2-butene-1,4-diamine in 50 milliliters of isopropanol. This reaction mixture was reacted for three hours with stirring under reflux conditions. High molecular weight polymer was found to be precipitated at room temperature. This reaction mixture was treated with 50 ml of aqueous 40% weight/volume N,N-dimethylamine, reacted at 500 C for one hour in a pressure reactor, then precipitated out with 200 ml of acetone. This precipitate was triturated with isopropanol, ethanol, is methanol at room temperature. The white precipitate was collected and dried in vacuo.
Nuclear magnetic resonance spectrum and other analysis methods confirmed the structure of the above polymer. A number average molecular weight was also estimated by NMR.
EXAMPLE 2 Utilizing the same synthetic and purification procedure as described in Example 1, using 1.69 g(0.0135 mol) of 1,4-dichloro-2-butene and 2.13 g (0.015 mol) ofN,NN',NNtetramethyl-2-butene-l,4-diamine, a white polymer was obtained.
EXAMPLE 3 1, 4 -Dichloro-2-butene (12.5 g, 0.1 mol) was added dropwise to 14.23 g (0.1 mol) ofNN,N,N,-tetramethyl-2-butene-,4-diamine in 150 ml of water at room temperature for a period of 30 minutes. This reaction mixture was reached at 50-55° C for two hours with stirring, transferred to a pressure bottle, and treated with 50 ml of aqueous 40% N,N- WO 97/29741 PCT/US96/01975 dimethylamine. This was reacted at 500 C for one hour and precipitated with 500 ml of acetone. By following the procedure described above in example 1, a white polymeric material was obtained and analyzed.
EXAMPLE 4 The procedure described in the synthesis of Example 1 was employed using 2.16 g (0.017 mol.) of 1,4-dichloro-2-butene and 2.46 g (0.017 mol.) ofN,N,N,N-tetramethyl-2butene-1,4-diamine, except that the reaction was performed in 20 ml of dimethylformamide at room temperature. The reaction mixture was raised to 500 C and stirred for one hour. A white precipitate was formed. This mixture was treated with 5.0 g of an aqueous solution of dimethylamine (40% w/v) and heated at 450 C for 40 minutes.
Following the purification process described above in Example 1, a white precipitate was obtained. Nuclear magnetic resonance spectrum and elemental analysis confirmed the structure of the polymer. A number average molecular weight was also estimated by
NMR.
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims (14)

1. An ophthalmic composition comprising a polymeric quaternary ammonium compound of the structure: W-CH 2 CH= CHCH 2 -[N+(CH 3 2 CH 2 CH=CHCH 2 ]n-W nX- wherein: W N(CH 3 2 X is a pharmaceutically acceptable anion; and n is an integer from 16 to 32 and wherein the compound is present at a concentration between about 0.00001 and about io percent by weight.
2. The ophthalmic composition of claim 1, wherein the polymeric quaternary ammonium compound is present at a concentration between about 0.00005 and about 0.05 percent by weight.
3. The ophthalmic composition of claim 2, wherein the polymeric quaternary ammonium compound is present a concentration between about 0.0001 and about 0.01 percent by weight.
4. A method of disinfecting a contact lens, comprising contacting a contact lens with a composition comprising an ophthalmically acceptable vehicle and a disinfecting amount of a substantially pure form of a polymeric quaternary ammonium compound of the structure: W-CH 2 CH= CHCH 2 -[N+(CH 3 2 CH 2 CH= CHCH 2 ]n-W nX wherein: W N(CH3)2; X is a pharmaceutically acceptable anion; and n is an integer from 16 to 32.
5. The method of claim 4, wherein n is an integer from 20 to 24.
6. The method of claim 4 or claim 5, wherein X is a halide. "2
7. The method of claim 6, wherein X is chloride.
8. The method of any one of claims 4 to 7, wherein the polymeric quaternary ammonium compound is present at a concentration between about 0.00001 and about 1.0 percent by weight.
9. The method of claim 8, wherein the polymeric quaternary ammonium compound is present at a concentration between about 0.00005 and about 0.5 percent by eight.
10. The method of claim 9, wherein the polymeric quaternary ammonium compound is present at a concentration between about 0.001 and about 0.05 percent by weight. [R \LIBZZ106203.doc:NJC
11. An ophthalmic composition comprising a polymeric quaternary ammonium compound of the structure: W-CH 2 CH= CHCH 2 -[N+(CH 3 2 CH 2 CH= CHCH 2 n W nX- wherein: W N(CH 3 2 X is a pharmaceutically acceptable anion; and n is an integer from 16 to 32 and wherein the compound is present at a concentration between about 0.00001 and about percent by weight, substantially as hereinbefore described with reference to any one of the Examples. "o
12. A method of disinfecting a contact lens, said method comprising use of polymeric quaternary ammonium compound of the structure: W CH 2 CH= CHCH 2 -[N+(CH 3 2 CH 2 CH CHCH 2 ]n-W nX C S* wherein: "W N(CH 3 2 i X is a pharmaceutically acceptable anion; and n is an integer from 16 to 32 and wherein the compound is present at a concentration between about 0.00001 and about percent by weight, substantially as hereinbefore described.
,13. A method of preparing an ophthalmic composition according to any one of claims 1 to 3 or 11, said method comprising combining an ophthalmically acceptable vehicle with a polymeric quaternary ammonium compound of the structure: W-CH 2 CH=CHCH 2 -[N+(CH 3 2 CH 2 CH= CHCH 2 n- W nX wherein: W N(CH 3 2 X is a pharmaceutically acceptable anion; and n is an integer from 16 to 32 wherein the compound is present in said composition at a concentration between about 0.00001 and about 1.0 percent by weight with an ophthalmically acceptable vehicle.
14. A method according to claim 13 wherein ophthalmically acceptable buffers, tonicity agents, surfactants and/or therapeutical agents are further combined with the polymeric quaternary Scompound and the ophthalmically acceptable vehicle. [R LIBZZ]06203 doc NJC 8 An ophthalmic composition prepared by a method according to claim 13 or claim 14. Dated 22 September, 1999 Alcon Laboratories, Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON &FERGUSON 9o *00 00*00 0. of 0:0 090 [R:\LII3ZZ]06203 doc NJC
AU49808/96A 1996-02-14 1996-02-14 Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials Ceased AU712908B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/001975 WO1997029741A1 (en) 1996-02-14 1996-02-14 Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials

Publications (2)

Publication Number Publication Date
AU4980896A AU4980896A (en) 1997-09-02
AU712908B2 true AU712908B2 (en) 1999-11-18

Family

ID=22254716

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49808/96A Ceased AU712908B2 (en) 1996-02-14 1996-02-14 Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials

Country Status (4)

Country Link
EP (1) EP0880351A4 (en)
JP (1) JP2000505486A (en)
AU (1) AU712908B2 (en)
WO (1) WO1997029741A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106561631B (en) * 2016-10-13 2020-12-11 刘鹏飞 A kind of saliva preservation solution and its preparation method and application

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3874870A (en) * 1973-12-18 1975-04-01 Mill Master Onyx Corp Microbiocidal polymeric quarternary ammonium compounds
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4444750A (en) * 1980-11-17 1984-04-24 Millmaster Onyx Group, Inc. Method of conditioning hair

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025653A (en) * 1975-04-07 1977-05-24 Millmaster Onyx Corporation Microbiocidal polymeric quaternary ammonium compounds
US4089977A (en) * 1976-11-24 1978-05-16 Kewanee Industries Polymeric anti-microbial agent
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
CA2009118C (en) * 1989-02-21 1996-02-27 Mary F. Mowrey-Mckee Method and composition for cleaning and disinfecting contact lenses
CA2041871C (en) * 1990-05-09 2000-07-11 Ruth A. Rosenthal Contact lens cleaning and disinfecting with combinations of polymeric quaternary ammonium compounds and enzymes
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3874870A (en) * 1973-12-18 1975-04-01 Mill Master Onyx Corp Microbiocidal polymeric quarternary ammonium compounds
US4444750A (en) * 1980-11-17 1984-04-24 Millmaster Onyx Group, Inc. Method of conditioning hair
US4407791A (en) * 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions

Also Published As

Publication number Publication date
AU4980896A (en) 1997-09-02
WO1997029741A1 (en) 1997-08-21
EP0880351A1 (en) 1998-12-02
JP2000505486A (en) 2000-05-09
EP0880351A4 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
US5512597A (en) Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials
EP0778731B1 (en) Ionene polymers containing biologically-active anions
US5942218A (en) Anti-infective material
US6051611A (en) Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobias
US7871602B2 (en) Use of bis-amines to enhance the antimicrobial activity of aqueous compositions
EP0731714B1 (en) Use of polyethylene oxide-containing polymeric quaternary ammonium compounds in pharmaceutical compositions
TW200410730A (en) Compositions with enhanced antimicrobial efficacy against acanthamoebae
US5683709A (en) Poly(benzalkonium salt) as an anti-microbial agent for aqueous drug compositions
US8329155B2 (en) Quaternary ammonium functionalized glycodendrimers, methods for the production and use thereof
JP3352091B2 (en) Phospholipid antibacterial composition
AU712908B2 (en) Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials
JP2550036B2 (en) Liquid composition for contact lens
US11044912B2 (en) Branched polymeric biguanide compounds and their uses
WO1996006603A1 (en) Polyalkylene oxide containing quaternary ammonium antimicrobial agents
CN103242521A (en) Polyhexamethylene guanidine propionate and preparation method thereof
JP5476365B2 (en) Interaction control of cationic biocides using unstable anionic polyelectrolytes
US8431751B1 (en) Polymeric quaternary ammonium compounds with vicinal hydroxy groups
CN106832267A (en) A kind of guanidine copolymer and preparation method thereof
US20160009861A1 (en) Branched Polymeric Quaternary Ammonium Compounds and Their Uses
AU4741199A (en) Ionene polymers containing biologically-active anions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired